Document is current

Article History

Received: 19 December 2024

Accepted: 3 March 2025

First Online: 29 March 2025

Declarations

:

: Julien Seneschal has received grants and/or honoraria from AbbVie, Bristol Myers Squibb, Calypso Biotech, Eli Lilly, Incyte, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi, Sun Pharmaceuticals, and Viela Bio and has patents on MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder and three-dimensional model of depigmenting disorder. Albert Wolkerstorfer has served as principal investigator for AbbVie, Avita Medical, Incyte, Novartis, and MSD; has served as an advisory board member for Incyte; has received research grants from Avita Medical and Lumenis; and has received devices from Humeca and PerfAction. Seemal R. Desai has received fees and/or honoraria as a consultant for Almirall, Avita, Bristol Myers Squibb, Cassiopea SpA, Dermavant Sciences, Dermira, Ferndale Laboratories, Foamix, Galderma Laboratories LP, Incyte, MC2 Therapeutics, Ortho Dermatologics, Pfizer, Scientis, Sente Labs, SkinCeuticals LLC, UCB, and Verrica Pharmaceuticals; has received stock options as a consultant for Gore Range Capital; has received honoraria as a speaker for Almirall and Ortho Dermatologics; has received grants/research funding as an investigator for AbbVie, AOBiome LLC, Atacama Therapeutics, Brickell Biotech, Dermavant Sciences, Incyte, Novan, and SkinMedica; has served as an advisory board member for the Foundation for Research & Education of Dermatology; is a stockholder of Gore Range Capital; and is a shareholder in PDP of Texas. Pearl Grimes has served as a consultant for Aclaris Therapeutics, Clarify Medical, DermaForce, Incyte, Proctor & Gamble, and Versicolor Technologies and a principal investigator for Aclaris Therapeutics, Allergan/SkinMedica, Clinuvel Pharmaceuticals, Incyte, Johnson & Johnson, L’Oreal, Merz Pharma, Pfizer, Thync Global Inc., and VT Cosmetics. Khaled Ezzedine is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. Amit G. Pandya has served as an investigator for Aclaris Therapeutics, Immune Tolerance Network, Incyte, and Pfizer; a consultant for AbbVie, Arcutis, Avita Medical, Chromaderm, Immune Tolerance Network, Incyte, Pfizer, TWi, Viela Bio, and Villaris; and holds stock options for Tara Medical and Zerigo Health. Deanna Kornacki and Shaoceng Wei are employees and shareholders of Incyte. Thierry Passeron has received grants and/or honoraria from AbbVie, ACM Pharma, Almirall, Amgen, Astellas, Bristol Myers Squibb, Calypso, Celgene, Galderma, Genzyme/Sanofi, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB, and Vyne Therapeutics; is the cofounder of NIKAIA Pharmaceuticals; and has patents on WNT agonists or GSK3β antagonist for repigmentation of vitiligo and on the use of CXCR3B blockers in vitiligo. David Rosmarin has received honoraria as a consultant or speaker, or for conducting clinical trials, for AbbVie, Abcuro, Almirall, AltruBio, Amgen, Arena Pharmaceuticals, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant Sciences, Dermira, Dualitas Therapeutics, EMD Serono, Galderma, Incyte, Janssen, Kymera, Kyowa Kirin, Lilly, Merck, Nektar Therapeutics, Novartis, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, Viela Bio, and Zura Bio; has received research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals; and has served as a paid speaker for AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, and Sanofi.

: TRuE-V1 and TRuE-V2 study protocols were approved by an institutional review board or ethics committee at each participating center. Both studies were conducted in accordance with the Declaration of Helsinki and adhered to Good Clinical Practice guidelines and applicable country-specific laws and regulations. All patients provided written informed consent or assent before study enrollment.